To describe the evolution in radical cystectomy (RC) care over 11 years at a referral centre.
Introduction
Radical cystectomy (RC) with pelvic lymph node dissection (PLND), represents the 'gold standard' approach to patients with muscle-invasive and refractory non-muscle-invasive bladder cancer (BCa) [1] . Despite centralization of BCa treatment to high-volume centres [2] , the introduction of enhanced recovery protocols [3] , standardization in surgical technique [4] and widespread adoption of minimally invasive surgery, RC is still considered a major surgical procedure and the risk of severe complications remains high [5] . Hospital readmission after major surgical procedures occurs in approximately one in eight patients, and the rate is even higher after cancer surgery [6] . Among patients with BCa, up to one in four is readmitted within 30 days of RC [6] .
Robot-assisted laparoscopy has decreased morbidity, mortality and readmissions in other major cancer surgery [6] and, to date, it has been considered a viable option for the treatment of BCa [1] . Robot-assisted RC (RARC) has been shown to be equivalent to open RC (ORC) in terms of oncological and functional outcomes [7] , but only few trials have presented evidence of similar intra-and peri-operative complications [8] [9] [10] [11] .
The aim of the present study was to describe the evolution of RC care over an 11-year period in a high-volume tertiary referral centre, focusing on major morbidity and mortality within 90 days of surgery.
Patients and Methods
After institutional review board approval, a retrospective analysis of our prospectively maintained database was carried out. We included patients who underwent RC for nonmetastatic BCa (cT1-4aN0M0) at our centre between January 2006 and December 2016. Those who received salvage cystectomy for unresectable cancers were excluded. We limited our study to patients who had continuous data available up to 90 days after surgery or death.
Data were reviewed with regard to demographic and anthropometric variables, American Society of Anesthesiologists (ASA) score, neoadjuvant chemotherapy (NAC), pre-and postoperative stage and pathology findings, surgical approach, type of urinary diversion and operating time. We also reviewed all the records of the patients who died, or were re-operated or admitted to the intensive care unit (ICU) within 90 days of RC, either at our institution or elsewhere in Sweden.
A lymphadenectomy extended up to the aortic bifurcation (extended PLND) was routinely attempted [1] ; if surgical contraindications were intra-operatively observed (e.g. enlarged nodes with an unsafe/unclear cleavage plane from important anatomical structures, significant blood oozing, iatrogenic blood vessel injuries), it was either omitted or performed according to a restricted template, at the discretion of the treating surgeon. According to international guidelines and institutional protocols, NAC was offered to patients with cT2-4N0M0 BCa eligible for cisplatin-based combination therapies [1] .
Within the study period, surgery was performed by 10 experienced surgeons. The surgical techniques for both ORC and RARC have been described elsewhere [12] [13] [14] . The type of urinary diversion (ileal conduit, Kock's abdominal reservoir, orthotopic ileal neobladder) was chosen with consideration given to patients' characteristics and preferences. We adopted a totally intracorporeal approach to robotic ileal conduits and neobladders in 2003.
In October 2012 an enhanced recovery protocol was introduced at our centre [15] . A stringent multidisciplinary approach to patients with BCa was endorsed in May 2005.
Statistical Analysis
Statistical analysis was performed using STATA software v. 13.1. Differences in distributions between the two types of surgery concerning different variables were tested using the Mann-Whitney U-test for continuous variables and the chisquared test for categorical variables.
We conducted crude and propensity score-weighted logbinomial regression analyses to assess the association between surgical approach and the overall risk of reoperation, ICU admission and death. Propensity score weights were calculated using logistic regression on surgical approach using the variables age, body mass index, NAC, clinical stage, type of urinary diversion, PLND, ASA score and operating time.
From the logistic regression model, stabilized inverse probability of treatment weights were calculated [16] . In the weighted log-binomial models, a sandwich estimator of the variances was used. An a value of 5% was considered as the threshold for significance.
Results
Overall, 907 consecutive patients underwent RC for BCa at our institution within the study period, of whom 93 were excluded because of missing data or unavailable follow-up information. This resulted in a final population of 814 patients, 620 men (76%) and 194 women (24%). Table 1 summarizes the patient characteristics.
Within the study period, a mean of 74 RCs were performed at our institution each year. We performed our first RARC in January 2003 and, thereafter, the percentage of minimally invasive approaches has been increasing year on year: 10% in 2006, 98% in 2012 and 100% from 2013 onwards (Fig. 1 ).
In most of the cases (71%), RC was offered to patients with carcinoma invading the bladder muscle, which was suspected to be non-organ-confined (cT ≥ 3) in 154 cases. A total of 176 (22%) and 58 (7%) other patients underwent surgery because of BCG failure and non-muscle-invasive disease at high risk of recurrence/progression, respectively.
Overall, 234 patients (29%) received NAC. The percentage of patients receiving preoperative chemotherapy increased over the years (from 12% in 2006 to 37% in 2016), thus a higher percentage of patients in the RARC cohort received cisplatin before surgery (36% vs 18%; P < 0.001).
On pathological examination, 448 patients (55%) were diagnosed with carcinoma invading the bladder muscle, which was organ-confined (pT2a-b) in 148 (18%) cases; concomitant carcinoma in situ was identified in 214 patients (26%). Nodal involvement was proven in 23% of the patients (172/752) who underwent PLND and most of them were pN1 (154/752; 20%).
Overall, 44 patients (5.4%) were admitted to the ICU within 3 months of surgery (28 after ORC, 16 after RARC; P = 0.005): most of them (38/44) were admitted only once. During their stay (median [interquartile range] time spent in ICU 4.5 [1] [2] [3] [4] [5] [6] [7] [8] [9] days), 40 patients improved and were discharged, while four died. Pneumonia, sepsis and postoperative bleeding were the most common reasons for admission, accounting for 22.7%, 22.7% and 15.9% of the cases, respectively. Within 90 days of RC, 73 patients (8.9%) required reintervention (41 after ORC, 32 after RARC; P = 0.015), mainly because of wound dehiscence (15/73; 20.5%), mechanical bowel obstruction (9/73; 12.3%) and postoperative bleeding (7/73; 9.6%).
The 90-day mortality rate was 2.9% (n = 24) and was significantly higher in the ORC cohort (4.6% vs 1.7%; P = 0.020). Surgery-related deaths accounted for 46% (11/24), while 42% (10/24) were cancer-related.
On crude analysis, patients undergoing RARC had a significantly reduced risk of ICU admission (relative risk [RR] 0.42, 95% CI 0.23-0.77; P = 0.005), reintervention (RR 0.58, 95% CI 0.37-0.90; P = 0.015) and death (RR 0.37, 95% CI 0.16-0.85; P = 0.020) within 3 months of RC; however, on weighted analysis, this association was not statistically significant ( Table 2 ).
Discussion
The standard of care for muscle-invasive and refractory nonmuscle-invasive BCa is RC with extended PLND [1] . Over recent years a widespread diffusion of minimally invasive surgery has been observed for the treatment of this disease and RARC became prevailing. In the USA, the percentage of RARCs noticeably rose (from 0.6% to 12.4%) between 2004 and 2010 [7] . Currently, in Denmark half of procedures are robot-assisted, while up until 2009 all RCs were performed with an open approach [2] . Similarly, a remarkable increase was observed at our centre (from 10% to 100%) within the study period and, from 2013 onwards, no more ORCs were performed.
Over the years, the baseline characteristics of the patients undergoing RC have remained stable; thus, in the present series, ORC and RARC populations were similar in terms of age, sex, body mass index and clinical stage, while patients in the RARC cohort were significantly less fit for surgery (42% with an ASA score ≥ 3 vs 30% in the ORC group; P < 0.001). In both groups, the main indication for RC was carcinoma invading the bladder muscle (72% vs 70% in the RARC and ORC cohorts, respectively; P = 0.097). Similar data are reported in other large series [17] .
A multidisciplinary approach to patients with BCa can help optimize the use of NAC [18] . Despite international guideline recommendations [1] , however, the rate of patients with carcinoma invading the bladder muscle receiving NAC accounts for 15-20% [19] . In our hospital, from its endorsement in 2005, the BCa multidisciplinary team have brought about a gradual increase in the rate of NAC. As a result, 29% of the patients overall (234/814) received cisplatin before surgery but the percentage was significantly higher in the RARC compared with the ORC cohort (36% vs 18%; P < 0.001). The Surveillance, Epidemiology and End Results Program showed a similar trend, and highlighted that NAC is more likely to be administered before RARC (19.4% vs 13.0%, P < 0.001) [17] .
Carcinoma invading the bladder muscle was identified in 55% of the cases overall and one in three of these was organ-confined. A diagnosis of pT0N0 was found in 23% of the patients (186/814) overall: 80/186 had received NAC. Interestingly, most of these (133/186) were in the RARC group. These results can be explained considering the higher rate of patients receiving NAC in the RARC cohort. In fact, patients treated with cisplatin-based chemotherapy before RC have a 10.5-45.5% complete pathological response rate [20] .
Lymphadenectomy was performed in the vast majority of the patients (82% overall), often (49.5%) up to the bifurcation of the aorta. Interestingly, despite no differences in operating time being highlighted in the present series, PLND was more commonly attempted in more recent years and during RARC, and was much more frequently extended (72% vs 19%; P < 0.001) in the RARC cohort.
The observed difference between ORC and RARC in terms of frequency and extent of PLND could either be the result of a growing recognition of the role of extended PLND in BCa treatment, or may be attributable to specific technical aspects of RARC that make it easier to perform an accurate lymphadenectomy. In fact, while some authors reported a higher rate of extended/superextended PLND after RARC [11] , others observed a common trend towards more frequent and more extended lymph node extirpations, regardless the surgical approach [21, 22] . Table 2 Crude and propensity score-weighted analyses to predict the risk of intensive care unit admission, reoperation and death within 90 days of open and robot-assisted radical cystectomy.
Outcome
Surgical approach % (n/N) Crude analyses P Analysis using propensity score weighting P In the present study, ileal conduit was the most frequently chosen type of urinary diversion in both groups; nonetheless, significantly more patients in the RARC cohort received an orthotopic ileal neobladder (34% vs 14%; P < 0.001). Although no level 1 evidence exists favouring one diversion type over another [1] , most institutions prefer neobladders and conduits, based on clinical experience [7, 11] . Even though robotic surgeons used to under-utilize neobladders [6] , a clear inverted trend was recently observed and, in several series, this type of urinary diversion represents the preferred choice [11] .
Radical cystectomy is indeed a morbid procedure, and many of the peri-/postoperative complications, mostly ClavienDindo grade <3, are thought to come from the reconstructive part of the procedure [23] . ORC is associated with a >60% complication rate (13-40% high grade in large series) and mortality up to 7% of patients [23] ; ICU admission occurs in up to 46% of cases [6] . RARC-related morbidity and mortality are deemed slightly lower: the rates of high-grade complications, ICU admission, reoperation and death within 90 days of surgery were reported to be 10-35%, 38%, 6% and 4.2%, respectively [6, 23, 24] . Several variables have been investigated in order to assess their capability in predicting unfavourable outcomes, but results are conflicting.
In the present series, the overall rates of re-intervention, ICU admission and death within 90 days of surgery were 8.9%, 5.4% and 2.9%, respectively. All these events were more common in the ORC group. Results from recently published randomized controlled trials comparing ORC with RARC highlighted that, although a slightly higher incidence of complications is observed after ORC, the difference between the groups is not statistically significant when only major complications (Clavien ≥3) are considered [9, 11] . Our 8.9% reoperation rate is in line with other RARC (8-37%) [4] and ORC (10-35%) [25] series. In the present study, 42/73 reoperated patients (57.5%) were from the ORC cohort (P = 0.015). Wound dehiscence (15/73; 20.5%), mechanical bowel obstruction (9/73; 12.3%) and postoperative bleeding (7/73; 9.6%) were the most common causes of surgical reintervention, in line with the findings published by Hussein et al. [5] . Our overall postoperative mortality rate was in line with the international literature (0-8%) [26, 27] . Fewer than half of the events were surgery-related. As previously mentioned, deaths were also twice as common in the ORC cohort (16 vs 8; P = 0.020). Overall, 44 patients (5.4%) were admitted to the ICU within 3 months of surgery and approximately one in three of these patients had undergone RARC (P = 0.005). Pneumonia, sepsis and postoperative bleeding were the most common reasons for admission, accounting for 22.7%, 22.7% and 15.9% of the cases, respectively. Each patient spent a median (interquartile range) of 4.5 (1-9) days in the ICU; all the patients improved and were discharged except for four who died.
According to our crude analysis, RARC was a significant predictor of all three outcomes considered: patients undergoing RARC had a more than halved risk of being admitted to the ICU (RR 0.42, 95% CI 0.23-0.77; P = 0.005), undergoing surgery (RR 0.58, 95% CI 0.37-0.90; P = 0.015) and dying (RR 0.37, 95% CI 0.16-0.85; P = 0.020) within 3 months of RC. On weighted analysis, however, this association was not statistically significant (Table 2) . These findings are in line with those reported in two meta-analyses demonstrating a lower complication rate after RARC than after ORC [12, 28] . Interestingly, although Hautmann et al. [29] highlighted that most of the adverse events after RC are correlated with urinary diversion, in the present series, the association with the risk of reoperation and ICU admission was not found to be statistically significant.
The present study has some limitations, the first of which is its retrospective design. Additionally, considering the need for continuous data available up to 90 days after surgery or death, we were forced to exclude all our patients living outside Sweden, resulting in a possible bias. These latter, however, accounted for <5% of all RC cases at our centre, therefore, their contribution to the overall population is deemed to be limited.
Another limitation is the lack of data regarding late complications: it has in fact been reported that most reoperations occur >90 days after RC [5] . Assessment of late complications, however, was not the aim of the present study and these may be considered in future investigations.
In addition, because we report our long-standing experience as a referral centre for the management of BCa, our findings may differ from those reported by other urologists from smaller centres worldwide, and the scarce number of patients experiencing unfavourable outcomes may limit the generalizability of our conclusions. Despite this, because centralization of care to high-volume centres is a common trend in many Western countries, the portrait of RC care we offer may be of interest to the reader.
Finally, we should specify that the present study was not designed to compare ORC and RARC approaches to BCa. During the study period, in fact, an enhanced recovery protocol was endorsed, the rate of patients receiving NAC increased year on year and 10 different surgeons with different expertise performed the cases, thus resulting in a significant bias.
Notwithstanding these limitations, this is one of the largest single-centre series describing the evolution of RC care for BCa and serious complications associated with RC, in a tertiary hospital, during an 11-year period and may provide new evidence that the RARC technique has the potential for better outcomes. During recent years, widespread diffusion of minimally invasive surgery has been observed for the treatment of BCa. In experienced hands, RARC does not require longer operating times, does not preclude extended lymph node retrieval and does not result in under-utilization of neobladder construction. Although RC is still considered a major surgical procedure and the risk of serious complications remains substantial, the introduction of the robot-assisted approach has coincided, according to our experience, with a reduction in the rate of ICU admission, reoperation and death within 3 months of surgery.
